

# Antibiotic Selection by Patient Population

| Patient Population                                                                                                         | Antibiotic selection                                                                                                                                                                                                                                                                                                                                                                                                 | Alternatives                                                                                                                                                       |
|----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Previously healthy < 30 days                                                                                               | Ampicillin and cefotaxime<br><br>Consider ampicillin and gentamicin if CSF pleocytosis not > 20 WBC/mm per pathway recommendations                                                                                                                                                                                                                                                                                   | Acyclovir if HSV work up performed                                                                                                                                 |
| Previously healthy > 30 days                                                                                               | Ceftriaxone                                                                                                                                                                                                                                                                                                                                                                                                          | Consider vancomycin for patients with known history of MRSA                                                                                                        |
| HemOnc BMT Suspected Infection Patients<br><b>Refer to "<a href="#">Individual Antibiotic Plan</a>" (IAP) if available</b> | If HemOnc Patient: Ceftazidime or Cefepime, per pathway; If BMT Patient: Meropenem<br><br><b>**PLUS</b><br>Consider adding gentamicin and vancomycin if hypotension despite 40 cc/kg NS or sooner if ill appearing and/or signs of severe sepsis.<br><br><b>**PLUS</b><br>Consider adding clindamycin or metronidazole if suspected perineal or intra-abdominal infection, respectively (unless receiving meropenem) | Cefepime OR meropenem per pathway recommendations<br>If concern for severe skin or perineal infection, consider use of "ED Necrotizing Soft Tissue Infection Plan" |
| Central Line Infection (not for HOSI/BMT)                                                                                  | Cefepime OR meropenem per pathway recommendations<br><br><b>**PLUS</b><br>Consider adding gentamicin AND vancomycin if ill appearing<br><br><b>**PLUS</b><br>Consider adding fluconazole per pathway recommendations                                                                                                                                                                                                 | Ciprofloxacin AND linezolid per pathway recommendations                                                                                                            |